Clinical Trials Browser

Phase 2/3 × Capecitabine × Breast × Clear all

NCT07413939 2026-04-09

BREnnA

Phase 2/3 Not yet recruiting

HER2-positive Breast Cancer

NCT06926868 2026-04-01

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Phase 2/3 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07366840 2026-01-26

BRIGHT

Phase 2/3 Not yet recruiting

Breast Neoplasms

NCT05288777 2025-04-18

Breast53

Phase 2/3 Recruiting

Breast Neoplasms

NCT03500380 2024-02-20

A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Phase 2/3 Unknown

Breast Diseases, Breast Neoplasms

NCT06268327 2024-02-20

Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy

Phase 2/3 Not yet recruiting

Breast Neoplasms

NCT04803539 2023-02-21

Artemis

Phase 2/3 Recruiting

Breast Neoplasms

NCT00397761 2021-02-17

Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer

Phase 2/3 Withdrawn

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00418028 2019-02-22

Standard Versus Continuous Capecitabine in Advanced Breast Cancer

Phase 2/3 Completed

195 enrolled 15 charts

Breast Neoplasms

NCT03423849 2018-02-06

The Maintenance Regimen and Revised Regimen for Advanced Breast Cancer Survivors After First-line Salvage Therapy

Phase 2/3 Unknown

Breast Neoplasms

NCT00684216 2017-09-14

Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer

Phase 2/3 Terminated

Breast Neoplasms, Neoplasm Metastasis

NCT02213744 2017-01-06

HERMIONE

Phase 2/3 Terminated

Breast Neoplasms

NCT01204437 2016-02-10

ICE-II

Phase 2/3 Completed

Breast Neoplasms

NCT01662128 2012-08-10

Efficacy and Safety Of Xeloda as Sequential Adjuvant Therapy After Chemotherapy in Breast Cancer

Phase 2/3 Unknown

Breast Neoplasms

NCT00049660 2012-07-18

Capecitabine Compared With Vinorelbine in Treating Women With Metastatic Breast Cancer

Phase 2/3 Terminated

Breast Neoplasms

NCT01415336 2011-08-11

AX Versus AC as Adjuvant Treatment for Node-Negative Breast Cancer

Phase 2/3 Unknown

Breast Neoplasms

NCT00201435 2008-05-20

Weekly Taxol Plus Xeloda® vs Taxotere q3wk Plus Xeloda® in the Treatment of Metastatic BC

Phase 2/3 Completed

Breast Neoplasms, Neoplasms